天康生物(002100) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥3,391,929,405.09, representing a 1.58% increase compared to ¥3,339,230,680.67 in the same period last year[4] - The net profit attributable to shareholders was -¥69,605,796.25, a decrease of 123.12% from ¥301,009,811.74 in the previous year[4] - The net cash flow from operating activities was -¥808,347,021.44, a decline of 238.17% compared to ¥585,028,585.93 in Q1 2021[4] - The company's total equity decreased from ¥7,783,303,372.25 to ¥7,603,798,910.94, representing a decrease of approximately 2.3%[23] - The net profit for the current period was a loss of CNY 108,566,710.19, compared to a profit of CNY 312,204,675.61 in the previous period, indicating a substantial decline[27] - The company reported a basic and diluted earnings per share of -0.05, down from 0.28 in the previous period[30] - The total comprehensive income for the current period was a loss of CNY 188,142,159.14, compared to a comprehensive income of CNY 312,204,675.61 in the previous period[30] Cash Flow - The company's cash and cash equivalents decreased from ¥3,424,083,819.49 at the beginning of the year to ¥2,322,436,762.83, representing a decline of approximately 32.3%[14] - Cash inflow from operating activities totaled CNY 3,162,894,211.54, a decrease from CNY 3,524,356,259.57 in the previous period[31] - The net cash flow from operating activities was -$808,347,021.44, a decrease from $585,028,585.93 in the previous period[34] - Cash outflow from operating activities totaled $3,971,241,232.98, compared to $2,939,327,673.64 previously[34] - The ending cash and cash equivalents balance was $2,175,960,504.84, up from $1,732,129,657.41 at the beginning of the period[37] Assets and Liabilities - The total assets at the end of the reporting period were ¥17,090,267,464.43, a decrease of 0.55% from ¥17,184,738,668.37 at the end of the previous year[4] - Accounts receivable increased significantly from ¥323,390,791.30 to ¥562,498,770.36, marking an increase of about 74%[17] - Inventory rose from ¥5,231,785,064.81 to ¥5,811,482,596.45, indicating an increase of approximately 11%[17] - Current liabilities decreased from ¥6,956,371,740.34 to ¥6,720,954,878.66, a reduction of about 3.4%[20] - Long-term borrowings increased from ¥1,964,000,000.00 to ¥2,254,000,000.00, reflecting a growth of approximately 14.7%[20] - The total liabilities increased from ¥9,401,435,296.12 to ¥9,486,468,553.49, an increase of about 0.9%[20] Expenses - Research and development expenses increased by 44.43% to ¥38,129,010.71 from ¥26,399,254.36 in the same period last year[6] - Total operating costs increased significantly to CNY 3,497,856,389.13 from CNY 2,991,259,996.71, marking an increase of about 17%[24] - The company experienced a significant increase in sales expenses, which rose to CNY 102,896,660.62 from CNY 87,342,342.14, an increase of approximately 17.5%[24] - The company reported a decrease in tax expenses to CNY 10,771,066.79 from CNY 13,843,938.13, a reduction of about 22.5%[27] Investment and Financing - The company received government subsidies amounting to ¥7,234,780.66, an increase of 25.47% from ¥5,766,068.36 in the same period last year[6] - The company’s investment income decreased by 54.58% to ¥8,040,381.48 from ¥17,701,587.34 in the previous year[6] - Cash inflow from financing activities was $1,021,500,000.00, an increase from $985,000,000.00 in the prior period[34] - Cash outflow from financing activities amounted to $1,144,078,555.00, down from $1,568,151,019.49 previously[34] - The company incurred tax payments of $21,987,065.28, a decrease from $41,290,626.14 in the prior period[34] - The company reported cash outflow for fixed assets and intangible assets acquisition at $127,769,859.28, down from $198,136,050.00[34]